ATE290857T1 - Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen - Google Patents

Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen

Info

Publication number
ATE290857T1
ATE290857T1 AT00904237T AT00904237T ATE290857T1 AT E290857 T1 ATE290857 T1 AT E290857T1 AT 00904237 T AT00904237 T AT 00904237T AT 00904237 T AT00904237 T AT 00904237T AT E290857 T1 ATE290857 T1 AT E290857T1
Authority
AT
Austria
Prior art keywords
kits
bretylium
preventing
cardiovascular diseases
containing compositions
Prior art date
Application number
AT00904237T
Other languages
English (en)
Inventor
Marvin B Bacaner
Maurice M Kreevoy
Original Assignee
Marvin B Bacaner
Maurice M Kreevoy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marvin B Bacaner, Maurice M Kreevoy filed Critical Marvin B Bacaner
Application granted granted Critical
Publication of ATE290857T1 publication Critical patent/ATE290857T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
AT00904237T 1999-01-08 2000-01-06 Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen ATE290857T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11514399P 1999-01-08 1999-01-08
US11656799P 1999-01-21 1999-01-21
PCT/US2000/000350 WO2000040232A2 (en) 1999-01-08 2000-01-06 Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions

Publications (1)

Publication Number Publication Date
ATE290857T1 true ATE290857T1 (de) 2005-04-15

Family

ID=26812887

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00904237T ATE290857T1 (de) 1999-01-08 2000-01-06 Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen

Country Status (10)

Country Link
US (1) US6482811B1 (de)
EP (1) EP1140054B1 (de)
JP (1) JP4750278B2 (de)
AT (1) ATE290857T1 (de)
AU (1) AU781996B2 (de)
CA (1) CA2358459C (de)
DE (1) DE60018704T2 (de)
IL (2) IL144199A0 (de)
MX (1) MXPA01007024A (de)
WO (1) WO2000040232A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884792B2 (en) * 1999-01-08 2005-04-26 Marvin B. Bacaner Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions
US20040019096A1 (en) * 2001-10-23 2004-01-29 Vlassios Andronis Novel formulations of carvedilol
BRPI0613670A2 (pt) * 2005-07-22 2011-01-25 Procter & Gamble composições para redução da incidência de arritmia induzida por fármacos
JP4750499B2 (ja) * 2005-08-01 2011-08-17 日華化学株式会社 イオン性液体並びにそれを用いた抗菌剤及び抗菌性繊維
EP2953627A4 (de) 2013-02-07 2017-03-29 Research Foundation Of The City University Of New York Fgf21-derivate und verwendungen davon
CA2998875C (en) 2015-09-17 2023-08-29 Ohio State Innovation Foundation Carborane compounds and methods of use thereof
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
JP2023518187A (ja) * 2020-03-11 2023-04-28 オハイオ・ステート・イノヴェーション・ファウンデーション カルボラン及びカルボラン類似体を使用したｔ細胞活性化の調節方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3038004A (en) 1958-04-18 1962-06-05 Burroughs Wellcome Co Quaternary ammonium compounds
US3441649A (en) 1966-08-18 1969-04-29 Univ Minnesota Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate
US3911125A (en) 1973-05-23 1975-10-07 Marvin B Bacaner Method of treating angina pectoris, coronary insufficiency, and preventing myocardial infarction
US4147768A (en) 1976-09-13 1979-04-03 Interx Research Corporation Enteric coated digoxin and therapeutic use thereof
US5288498A (en) 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
HU207452B (en) 1986-03-21 1993-04-28 Eurasiam Lab Method for producing therapeutical preparations containing active ingredient having biologicallu active protein structure
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
US5036106A (en) 1989-09-05 1991-07-30 Bacaner Marvin B Methods for the treatment of disorders of the cardiac vascular system
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
JP3355593B2 (ja) 1994-08-19 2002-12-09 信越化学工業株式会社 固形腸溶製剤の製造方法
US5733575A (en) 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
JP3149122B2 (ja) 1994-11-07 2001-03-26 信越化学工業株式会社 固形腸溶製剤のコーティング用基剤
US5686106A (en) 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US5980951A (en) 1996-04-10 1999-11-09 Merck & Co., Inc. Oral coated active drugs

Also Published As

Publication number Publication date
CA2358459A1 (en) 2000-07-13
JP2002534379A (ja) 2002-10-15
JP4750278B2 (ja) 2011-08-17
DE60018704T2 (de) 2006-05-04
WO2000040232A3 (en) 2000-11-23
US6482811B1 (en) 2002-11-19
AU2602300A (en) 2000-07-24
MXPA01007024A (es) 2002-03-27
IL144199A (en) 2006-10-05
AU781996B2 (en) 2005-06-23
EP1140054A2 (de) 2001-10-10
EP1140054B1 (de) 2005-03-16
IL144199A0 (en) 2002-05-23
WO2000040232A2 (en) 2000-07-13
CA2358459C (en) 2011-05-24
DE60018704D1 (de) 2005-04-21

Similar Documents

Publication Publication Date Title
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
DE69905476D1 (en) Phosphonsaürederivate als ptp-1b-inhibitoren
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE235244T1 (de) Zusammensetzung zur behandlung und prävention neurologischer und pathopsychologischer krankheiten
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE60326069D1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
ATE367380T1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE59909607D1 (de) Tan-1057 derivate
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
JO2724B1 (en) 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE271384T1 (de) Arylnitron therapeutische mittel zur behandlung von entzündlichen darmerkrankungen
SE9901273D0 (sv) Novel compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties